Lovastatin synergistically enhances the efficacy of TNF-related apoptosis-inducing ligand (TRAIL) in human refractory prostate cancer cells via the upregulation of death receptor 4 (DR4) [149]. This evidence concerns the gene TNFSF10 and prostate carcinoma.